Renaissance Technologies’s TransCode Therapeutics RNAZ Stock Holding History

Renaissance Technologies’s Portfolio RNAZ Stock Details RNAZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-5	Closed	-$31K	–	4007
2023 Q4	$31K	Buy	+5	New	+$56.2K	﹤0.01%	3529
2023 Q1	–	Hold	0	–	-$9K	–	4321
2022 Q4	–	Hold	0	–	–	–	4041
2022 Q3	–	Hold	0	–	-$25K	–	4348
2022 Q2	–	Hold	0	–	–	–	4100

Other funds holding RNAZ

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

FPFS

First Personal Financial Services Charlotte, North Carolina $473M AUM 28.33% 1-Year Est. Return

Renaissance Technologies's RNAZ Position: Q1 2024 in Review

Renaissance Technologies sold out of TransCode Therapeutics (RNAZ) in Q1 2024, closing a stake of 5 shares — an estimated $31K sold.

Renaissance Technologies first reported a position in RNAZ in Q4 2023 and held it in 1 quarter. The position peaked at $31K in Q4 2023. 4 funds tracked by Wall St. Rank hold RNAZ as of Q1 2024.

Renaissance Technologies reported no remaining TransCode Therapeutics position as of Q1 2024 after selling out during the quarter.
Renaissance Technologies sold 5 TransCode Therapeutics shares in Q1 2024, an estimated $31K.
Renaissance Technologies first reported a position in TransCode Therapeutics in Q4 2023 and held it in 1 quarter.
Renaissance Technologies's TransCode Therapeutics position peaked at $31K in Q4 2023.
4 funds tracked by Wall St. Rank held TransCode Therapeutics as of Q1 2024.

Based on Renaissance Technologies's 13F filing for Q1 2024, filed 13 May 2024.